Experts push for rabies vaccine in children before dog bites
THIRUVANANTHAPURAM: Administering the rabies vaccine before a dog bite may seem unusual to many parents. However, a rise in rabies infections among children has prompted health experts to recommend pre-exposure prophylaxis (PrEP) for all children under the age of 14 before any animal attack occurs. The Indian Academy of Pediatrics (IAP) and the Kerala Government Medical Officers Association (KGMOA) have jointly called for the inclusion of PrEP in child healthcare protocols.
Providing general immunity against rabies not only helps prevent deaths but also reduces the need for expensive rabies immunoglobulin (RIG), which is administered in addition to the standard post-bite vaccine. While previously seen as an excessive measure, the surge in rabies cases and the high cost of post-exposure treatment have made PrEP a necessary intervention.
Dog bite cases in Kerala have seen a dramatic rise - from 60,000 in 2013 to over 3.16 lakh in 2024. Human fatalities have also increased, with 14 rabies deaths reported so far this year, and an annual toll of 20-25 deaths in recent years. Children remain the most affected. Globally, rabies claims around 59,000 lives annually, with 18,000-20,000 of those in India. Of these, nearly 40% are children.
'Children are most vulnerable. Many have died even after receiving the vaccine post-bite due to the challenging nature of the bites,' said Dr Riaz I, president of the IAP Kerala Chapter. 'We recommend PrEP for school-going children to prevent such tragedies.' Dr Riaz also pointed out the difficulty of administering rabies serum in sensitive bite locations like eyes, underlining the advantage of pre-exposure vaccination.
The KGMOA has urged the state to form a task force to implement a universal PrEP programme, starting with children.
'Over 35% of dog bite victims are children. We must prioritise them,' said Dr Sunil P K, KGMOA president.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
7 hours ago
- Mint
A new shot prevents HIV—and breathes new life into a stagnant biotech
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV—a milestone in the decadeslong fight against a once-devastating disease. For Gilead Sciences, the dominant player in HIV treatment, the breakthrough is doing what years of splashy but underwhelming acquisitions failed to achieve: It has Wall Street paying attention again. Since reporting last June that just two annual shots of lenacapavir prevented all HIV infections in a study of women and girls, shares have surged 73%. Gilead still isn't very expensive: It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, and hardly a stretch for a company on the cusp of a new product cycle. Investors might fear they have seen this movie before. A decade ago, Gilead stock soared on excitement over its hepatitis C cure, only to stall once most patients had been treated and the market dried up. The company then fell into value-trap territory, weighed down by sluggish growth and a string of underwhelming cancer deals. This time could be different—but only if Gilead can execute. Over 400,000 people in the U.S. are currently on pre-exposure prophylaxis, or PrEP—a medication that protects against HIV infection. To hit the $4 billion in annual sales that some analysts are forecasting by the end of the decade, the company will need to not only convert a big chunk of existing patients but also expand the overall market both at home and abroad. Gilead expects the number of users in the U.S. to grow to over one million in the next decade. The early signs are promising. For starters, the market is growing fast. Sales of Gilead's daily pill Descovy rose 38% last quarter from a year ago, while GSK's Apretude—a long-acting injection given every two months—jumped 63%. Secondly, many current and potential users say they would prefer a longer-acting injection. A Jefferies survey of more than 500 PrEP users found that 95% would switch to a twice-yearly injection. In an interview, Gilead's Chief Commercial Officer Johanna Mercier said the key advantage of the company's upcoming HIV prevention shot isn't just efficacy but adherence. 'We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," she said, citing data showing that many patients struggle to stay consistent with oral PrEP. Still, hurdles remain. Stigma continues to hinder PrEP uptake, particularly outside the core demographic of white men who have sex with men. Black Americans account for 39% of new HIV diagnoses but just 14% of PrEP users. Expanding access to underserved populations will require continued insurance coverage. While most current users are covered by commercial insurance, Medicaid will be key to reaching lower-income groups—making recent GOP proposals to cut the program a potential threat to Gilead's growth strategy. Another risk, according to RBC Capital Markets analyst Brian Abrahams, is cannibalization. Gilead's daily pill Descovy currently accounts for 40% to 45% of the PrEP market, so some of the lenacapavir growth could come at the expense of its existing business. But Mercier is confident the new product will expand the market both in the U.S. and globally. Gilead is working with governments in countries such as the U.K., where PrEP awareness is low, and planning broader rollout in low-income countries through partnerships with global health organizations. 'We're thinking globally about the public health impact we can have," she said. Gilead's growth outlook means it is, for now, steering clear of the patent cliff that is about to hit much of the industry as multibillion-dollar blockbuster drugs face generic competition. Gilead's HIV blockbuster, Biktarvy—which is prescribed after infection—retains exclusivity until 2033, with several potential successors already in the pipeline. Beyond HIV, Gilead is beginning to show signs of turning the corner in cancer, a space where past acquisitions have frustrated investors. There is growing excitement around Trodelvy—an antibody-drug conjugate acquired via its $21 billion Immunomedics deal—after data showed it delayed progression in an aggressive form of breast cancer when combined with Merck's Keytruda. Meanwhile, Gilead's cell therapy program is gaining traction, with the company aiming to challenge Johnson & Johnson in the multibillion-dollar multiple myeloma market, explains Traver Davis, a healthcare strategist at Citi. 'They have been hammered for their acquisitions and execution on the oncology side of the business in the last few years," said Davis. 'The narrative on that is definitely turning." Gilead spent years trying to move beyond HIV. In the end, it might be HIV prevention that finally delivers the breakthrough investors have been waiting for. Write to David Wainer at
Time of India
6 days ago
- Time of India
Stray dog bites 10 people in Mettupalayam
COIMBATORE: A stray dog bit ten people at Mani Nagar in Mettupalayam on Thursday night. All of them received treatment in Mettupalayam Government Hospital. While most of them sustained minor injuries, a couple had more severe bite marks and were examined by a surgeon. Tired of too many ads? go ad free now They have since been declared healthy. A health official in the Mettupalayam GH stated that all the victims were vaccinated against rabies. "People with minor bites were administered anti-rabies vaccine (ARV), and those with severe bite marks were given an additional rabies immunoglobulin (RIG). On Friday morning, they were examined by a surgeon. They have been declared safe. No abnormalities have been reported. All ten people were treated as outpatients," the official added. Meanwhile, based on the direction of Mettupalayam municipality commissioner R Amudha, municipality workers started to capture stray dogs for sterilising them. Around five stray dogs were captured on Friday. There is no animal birth control (ABC) centre in Mettupalayam municipality. Recently, the council passed a resolution to establish an ABC centre.
The Hindu
28-05-2025
- The Hindu
Shortage of doctors hits Peravoor taluk hospital in Kannur; KGMOA stages protest
Severe shortage of doctors has hit the functioning of the Peravoor taluk hospital, prompting the Kerala Government Medical Officer's Association (KGMOA) to launch a protest demanding urgent intervention by the Health department in the matter. KGMOA district president V.S. Jidhin said the hospital, which has only 14 doctors including the superintendent, was grappling with three vacancies with one doctor on long leave and another assigned to a tribal mobile unit. The only gynaecologist is forced to work round the clock, and the services of the night emergency department have been suspended due to staff crunch. 'Ideally, five doctors are required daily to manage emergency services in a taluk hospital, but the Peravoor hospital now relies on just two. This has forced even specialists to take up emergency duties, disrupting the general outpatient services that cater for over 700 patients daily,' he said. The situation is expected to worsen with the onset of the monsoon as the hospital, the only major medical facility in the region, is currently unable to run general medicine, paediatric and fever clinics, he added. The KGMOA alleged that the situation got aggravated due to the redeployment of doctors attached to the hospital to non-health related duties, including the Kottiyoor festival, in violation of government directives. The association pointed out that two doctors were transferred out of the district recently, but there were no replacements for them. With over 80 vacancies of doctors reported across the district, the KGMOA said that arbitrary assignments and keeping vacancies unfilled hit both routine care and disease control during the monsoon season. The association demanded immediate filling of vacancies.
